Green light: EU authority approves more vaccine plants for BioNTech and Moderna - stocks finally dark red

As with BioNTech and Pfizer, modern mRNA agents can be manufactured in plants. The plants should go into operation immediately, with no further approval required from the European Union Commission.

A new production line has been approved at the BioNTech location in Marburg. This will help increase production capacity for the BioNTech active ingredient to approximately 410 million doses, EMA explained. In addition, the vaccine from Mainz-based manufacturer BioNTech and its US partner Pfizer can now be produced at Delfarm in Saint-Rémy sur-Avre, France. Up to 51 million cans are included here.

In addition, the EMA approved several production facilities for Moderna Vaccine in the USA. In addition, the authority last month approved an increase in production at two plants, including at Swiss contract manufacturer Lonza. As a result of these moves, an additional 40 million vaccine doses from a US manufacturer could be delivered to the EU in the third quarter of this year.

After vaccine producers were able to secure papers on Monday, BioNTech stock fell 3.64 percent to $368.20 by the NASDAQ closing bell on Tuesday, while Pfizer stock eventually fell 3.12 percent to $48.37 on the NYSE. . Shares of Moderna closed down 3.33 percent on the NASDAQ at $390.80.

Bangalore (Reuters)

Image Source: Pavlo Gonchar / SOPA Images / LightRocket via Getty Images, Ascannio / Shutterstock.com